Spanish IT Stock News

BME:PSG
BME:PSGCommercial Services

3 Spanish Defense Stocks Retail Investors Are Watching After The Ceuta Border Crisis

The sudden arrival of 60,000 migrants into Spain’s Ceuta enclave has pushed border security, surveillance and regional stability into the spotlight. For investors, this kind of shock can quickly reshape how capital flows into Spanish defense and security stocks that are directly exposed to the news. Some companies may see stronger demand for their technology and services. Others could simply attract more attention as policies and budgets adjust. This article walks through 3 stocks from a...
BME:AMS
BME:AMSHospitality

Amadeus (BME:AMS) Stock Faces Booking Friction Despite Solid Cash Flow

Amadeus IT Group stock has quietly ground higher in recent months, with a 3 month gain of about 8.9% and a close at €53.34 on 31 July. The market has been rewarding the story. The headline from this earnings release is more nuanced. Revenue for Q1 2026 sat at €1,682.6m and basic earnings per share were €0.83, while management kept free cash flow and margin discipline in clear focus. The real question now is whether that cash generation and margin profile justify the current P/E of 16.1x over...
BME:BBVA
BME:BBVABanks

Banco Bilbao Vizcaya Argentaria (BME:BBVA) Following Strong Q2 And Buyback Faces A Pricey Fair Value View

Banco Bilbao Vizcaya Argentaria (BME:BBVA) stock is in focus after the bank reported second quarter 2026 net income of €3,062 million and announced a new €2b share buyback alongside higher regional guidance. See our latest analysis for Banco Bilbao Vizcaya Argentaria. Banco Bilbao Vizcaya Argentaria’s latest results and €2b buyback have landed after a strong run, with a 10.25% 1 month share price return and a 75.63% 1 year total shareholder return signalling strong momentum built over several...
BME:BBVA
BME:BBVABanks

BBVA (BME:BBVA) Stock Rallies Behind Loan Growth And Fresh Buybacks

BBVA stock closed at €24.2 after the market weighed in on its Q2 2026 numbers that delivered a punchy headline. The group posted net income of €3.062b for the quarter and €6.051b for the first half, with return on tangible equity around the low 20s that management calls best in class among big European banks. Short term traders are focused on the recent double digit share price gains. Long term investors are looking at a bank combining strong profitability with rising loans and a growing...
BME:PHM
BME:PHMBiotechs

Pharma Mar (BME:PHM) Stock Faces Clinical Setback Despite Royalty Strength

Pharma Mar stock closed at €80.15 after the market absorbed its half year 2026 update, leaving investors weighing a flat near term share price against a very different earnings picture. The company delivered resilient recurring oncology revenues and stayed cash generative, yet quarterly profit slipped into a small loss of €0.972m even as trailing twelve month earnings from continuing operations reached €56.126m. The real story now sits on the longer horizon. Royalty growth, the Zepzelca...
BME:RED
BME:REDElectric Utilities

Redeia (BME:RED) Stock Sees Revenue Growth Clash With Softer Profit Margins

Redeia Corporación went into this print priced for steadiness, with the stock roughly flat over the past quarter. The latest move around €15.32 shows investors still testing that slow growth, high income story. The headline from Q2 is a squeeze on profitability. Quarterly net income of €123.7 million sits below Q1, even as revenue holds at €458.4 million, and trailing net profit margins are softer than last year. For a regulated grid operator that many holders treat as a bond substitute,...
BME:COXG
BME:COXGRenewable Energy

Cox Infrastructure Group (BME:COXG) Stock Revenue Climbs As Losses Deepen

Cox Infrastructure Group shares came into this earnings print on the back foot, with the stock down around 6% over the past month, yet the headline story is not the share price. The real shock is on the income line. Over the last twelve months the company swung from profit to a loss of €56.8 million, even as revenue reached €1.53b. That profit squeeze is what the market is trying to price in today, and it sets the emotional tone for how investors will read the rest of this report. Concerned...
BME:ALM
BME:ALMPharmaceuticals

Is Almirall (BME:ALM) Undervalued After Half Year Results And Guidance Reiteration?

Almirall (BME:ALM) is in focus after reporting half year 2026 results on 24 July, alongside a reiteration of full year guidance for net sales growth of 9% to 12%. See our latest analysis for Almirall. The reiteration of guidance comes after a mixed year for Almirall’s share price, with a 7-day share price return of 4.75% and a year-to-date share price return down 11.16%. The 3-year total shareholder return of 39.16% shows stronger longer term momentum. If today’s update has you thinking about...
BME:ECR
BME:ECRChemicals

Ercros (BME:ECR) Stock Returns To Profit But Durability Remains Unclear

Ercros stock closed at €3.485, with recent returns barely moving the needle over the past week and month. The share price looks calm on the surface. The earnings print is anything but. Q2 revenue landed at €214.397 million and flipped the company back into profit with net income of €9.705 million, after a run of quarterly losses. For a chemicals producer that has been unprofitable over the last twelve months and is expected to stay that way in forecasts, this single profitable quarter stands...
BME:VID
BME:VIDPackaging

Vidrala (BME:VID) Reaffirmed Targets, Is The Stock Still Cheap?

Why Vidrala’s latest earnings matter for shareholders Vidrala (BME:VID) has moved back into focus after its half year 2026 earnings on 23 July, with rising profit, firmer margins and a clear reaffirmation of full year financial targets. For the six months to 30 June 2026, Vidrala reported sales of €755.04 million compared with €751.14 million a year earlier. Net income was €117.4 million against €107.84 million, with basic earnings per share at €3.36 versus €3.0667. See our latest analysis...
BME:ART
BME:ARTElectrical

European Stock Picks Possibly Trading Below Intrinsic Value Estimates In July 2026

The European stock market has shown resilience, with the pan-European STOXX Europe 600 Index rising by 0.46% amid robust corporate earnings and geopolitical tensions impacting oil prices. As investors navigate these complex conditions, identifying stocks that may be trading below their intrinsic value can present opportunities for those seeking potential growth in a volatile environment.
BME:ENG
BME:ENGGas Utilities

Enagás (BME:ENG) H1 Earnings Put Its Undervalued Narrative Back In Focus

How Enagás earnings set the context for the stock Enagás (BME:ENG) has just reported half year 2026 results, with sales of €444.63 million and net income of €126.91 million, both lower than the same period a year earlier. Basic and diluted earnings per share from continuing operations were €0.49, compared with €0.68 a year ago. This gives investors fresh information to reassess how the stock’s current price reflects these figures. See our latest analysis for Enagás. Since the H1 2026 earnings...
BME:SAB
BME:SABBanks

Banco de Sabadell (BME:SAB) Stock Faces Margin Pressure As Q2 Net Interest Margin Slips To 1.79%

Banco de Sabadell (BME:SAB) has reported Q2 2026 results with total revenue of €1,396 million and net income of €624 million, setting the tone for how the rest of the year may shape up for shareholders. The company has seen quarterly revenue move from €1,362 million in Q4 2025 to €1,046 million in Q1 2026 and then to €1,396 million in Q2 2026, while basic EPS tracked at €0.0776 in Q4 2025 and €0.0705 in Q1 2026. This gives investors a clearer view of how the top and bottom lines are pacing...
BME:GRF
BME:GRFBiotechs

Does Grifols (BME:GRF) Phase 3 Bet Signal a Deeper Pivot in Its Immunology Strategy?

Grifols recently reported that the first patients have been dosed in two Phase 3 trials to expand U.S. labels for its flagship immunoglobulin therapies, GAMUNEX-C and XEMBIFY, targeting secondary immunodeficiency in certain blood cancers and chronic inflammatory demyelinating polyradiculoneuropathy. This push to broaden indications for existing plasma-derived products highlights how Grifols is trying to deepen its presence in complex, chronic immune-related conditions where immunoglobulin...
BME:ART
BME:ARTElectrical

European Export Stocks Getting A Tariff Edge In The US

The new US tariff regime under Section 301 is quietly reshaping the playing field for global exporters, and European stocks are right in the middle of it. With lower duties for key countries like France, the UK, Germany, Spain, Belgium, and Italy, and higher rates for rivals such as Brazil, some European exporters now sit in a more favorable position in US trade. This article looks at how that shift connects to large European companies on our European Exporters screener and reveals 3 stocks...
BME:CIE
BME:CIEAuto Components

Is CIE Automotive (BME:CIE) Undervalued After Strong Half Year Earnings?

CIE Automotive (BME:CIE) has drawn attention after reporting half year 2026 earnings, with sales, revenue, net income and earnings per share all higher than the figures reported a year earlier. See our latest analysis for CIE Automotive. Despite the stronger half year figures, CIE Automotive’s recent share price performance has been weak, with the stock at €25.8 and a year to date share price decline of 14.99%. However, the 5 year total shareholder return of 17.34% points to a more resilient...